Lineage Cell Therapeutics (LCTX) Exchange Rate Effect (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Exchange Rate Effect of -$5000.0 for Q1 2026, up 93.15% year-over-year from -$2588.7 in Q1 2025, and down 102.78% quarter-over-quarter from $180000.0 in Q4 2025.
Powered by 
Analysis
Lineage Cell Therapeutics (LCTX) Exchange Rate Effect (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Exchange Rate Effect history runs 17 years deep, the most recent figure standing at -$5000.0 for Q1 2026.
- In Q1 2026, Exchange Rate Effect rose 93.15% year-over-year to -$5000.0; the TTM figure through Mar 2026 stood at $464000.0 (up 573.47% YoY), while the FY2025 annual figure was $396000.0, up 516.84% from the prior year.
- Exchange Rate Effect for Q1 2026 stood at -$5000.0, down from $180000.0 in the prior quarter.
- The five-year high for Exchange Rate Effect was $293000.0 in Q2 2025, with the low at -$634000.0 in Q3 2022.
- The 5-year median for Exchange Rate Effect is -$70000.0 (2024), against an average of -$48647.1.
- The sharpest annual moves came in 2022 and 2025: Exchange Rate Effect sank 7144.44% in 2022, then surged 620.0% in 2025.
- Lineage Cell Therapeutics' Exchange Rate Effect stood at -$78000.0 in 2022, then surged by 461.54% to $282000.0 in 2023, then sank by 91.13% to $25000.0 in 2024, then soared by 620.0% to $180000.0 in 2025, then plunged by 102.78% to -$5000.0 in 2026.
- Business Quant data shows LCTX's Exchange Rate Effect at -$5000.0 in Q1 2026, $180000.0 in Q4 2025, and -$4000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -2.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.84 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -287,000.00 |
| 10 | Lineage Cell Therapeutics | 270.71 Mn | 213.99 Mn | 1.07 Mn | 259,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 259,000.00 |
| Mar 31, 2026 | -5,000.00 |
| Dec 31, 2025 | 180,000.00 |
| Sep 30, 2025 | -4,000.00 |
| Jun 30, 2025 | 293,000.00 |
| Mar 31, 2025 | -73,000.00 |
| Dec 31, 2024 | 25,000.00 |
| Sep 30, 2024 | 38,000.00 |
| Jun 30, 2024 | -88,000.00 |
| Mar 31, 2024 | -70,000.00 |
| Dec 31, 2023 | 282,000.00 |
| Sep 30, 2023 | -340,000.00 |
| Jun 30, 2023 | -92,000.00 |
| Mar 31, 2023 | -100,000.00 |
| Dec 31, 2022 | -78,000.00 |
| Sep 30, 2022 | -634,000.00 |
| Jun 30, 2022 | -119,000.00 |
| Mar 31, 2022 | -42,000.00 |
| Dec 31, 2021 | 14,000.00 |
| Sep 30, 2021 | 9,000.00 |